Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 13;2:11. doi: 10.1038/s41525-017-0016-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — Improved efficacy of the CDMV strategy. ORs for existing designs of target CpG sites are shown as well as ORs for the strategy. CDMV-Mono and CDMV-CD4T are sets of target CpG sites determined by using the CDMV strategy from our comprehensive DNAm profiles of monocytes and CD4⁺ T cells, respectively. CDMV-Mono includes 2.0 million CpG sites and CDMV-CD4T is composed of 3.0 million CpG sites. The OR was estimated by comparing the biomarker likelihood of each set of target CpG sites with that of CpG sites probed by HM450. The 95% CIs are represented as solid lines. a ORs for population-based and case-control EWASs. The ORs were estimated based on 269 CpG sites previously identified in population-based and/or case-control EWASs. b ORs for population-based EWASs. The ORs were estimated based on 47 CpG sites previously identified in population-based EWASs. c ORs for case-control EWASs. The ORs were estimated based on 225 CpG sites previously identified in case-control EWASs. CpGiant SeqCap Epi CpGiant, HM450 HumanMethylation450, Rep replication, RRBS reduced-representation bisulfite sequencing, SureSelect SureSelect Human Methyl-Seq